Pub Date : 2026-02-12DOI: 10.1016/j.ebiom.2026.106168
Jean Claude Semuto Ngabonziza, Khairunisa Suleiman, Nouh Saad Mohamed, Gilbert Rukundo, Marie Fidele Muremba, James Kagame, Jean Claude Mugisha, Hervé Rutebuka, Eric Remera, Emmanuel Edwar Siddig, Schifra Uwamungu, Emery Hezagira, Sylvere Mugumya, Benjamin Niyitegeka, Jean Baptiste Byiringiro, Patrick Migambi, Manasseh Wandera Gihana, Sarah Girdwood, Jean Baptiste Mazarati, Nick Banks, Aurélien Macé, Rita Makabayi Mugabe, Richard T Lester, Albert Tuyishime, Ayman Ahmed, Vanessa Fargnoli, Claude Mambo Muvunyi, Paula Akugizibwe, Rigveda Kadam
Background: Community health workers (CHWs) play a vital role in identifying patients within the community. To enhance their decision-making and reduce unnecessary referrals, Rwanda introduced a digital integrated disease screening tool (d-IDS), embedded within the national community Electronic Medical Records (cEMR) system. This study aimed to design, integrate, and evaluate the d-IDS to support its broader national scale-up.
Methods: This study employed a pre-post effectiveness-implementation hybrid design to implement the d-IDS and evaluate its effectiveness in improving patient management at the community level in five districts during April-July 2024. The d-IDS was designed into a single decision-support workflow embedded within the cEMR platform, and deployed on CHWs' smartphones. The workflow automatically guides CHWs through case registration, symptom assessment, diagnostic testing, and treatment or referral decisions. The d-IDS tool consolidated the screening processes for tuberculosis, malaria, pneumonia, and diarrhoeal diseases. Referral data extracted from the cEMR following d-IDS implementation and retrospective data from similar period (April-July 2023) collected under the paper-based approach; Standard of Care (SOC), were analysed using Chi-square tests. Qualitative feedback from CHWs were gathered through structured interviews to assess acceptability and feasibility.
Findings: The implementation of d-IDS led to a statistically significant 24.2% reduction in overall referrals to health facilities (p < 0.0001) when compared to the SOC period. Of the 3060 individuals screened using the d-IDS, 45.6% triggered further assessment, and 1687 (55.1%) were successfully managed by CHWs at the community level. Notably, in Rwamagana district, referral rates dropped from 79.8% to 32.5%, a 59.2% reduction (p < 0.0001). CHWs reported that d-IDS improved workflow efficiency, data accuracy, and decision-making compared to the paper-based approach, especially with features like offline functionality and symptom-guided screening protocols.
Interpretation: The findings confirm that d-IDS is both feasible and acceptable for CHW use in community settings. It improves community-based patient management and reduces the burden on health facilities. However, close follow-up mechanisms are necessary to ensure early detection of any worsening conditions. These promising results support the future national rollout of d-IDS as a scalable solution to strengthen primary healthcare and CHW-led service delivery.
Funding: The study received financial support from the United Kingdom (FCDO 40105983), Canada (DFATD 7429348) and Germany (BMZ ACT Accelerator support 25.04.2022).
{"title":"Implementation and evaluation of a community health workers-led digital integrated diseases screening system to provide healthcare for patients at community level in Rwanda.","authors":"Jean Claude Semuto Ngabonziza, Khairunisa Suleiman, Nouh Saad Mohamed, Gilbert Rukundo, Marie Fidele Muremba, James Kagame, Jean Claude Mugisha, Hervé Rutebuka, Eric Remera, Emmanuel Edwar Siddig, Schifra Uwamungu, Emery Hezagira, Sylvere Mugumya, Benjamin Niyitegeka, Jean Baptiste Byiringiro, Patrick Migambi, Manasseh Wandera Gihana, Sarah Girdwood, Jean Baptiste Mazarati, Nick Banks, Aurélien Macé, Rita Makabayi Mugabe, Richard T Lester, Albert Tuyishime, Ayman Ahmed, Vanessa Fargnoli, Claude Mambo Muvunyi, Paula Akugizibwe, Rigveda Kadam","doi":"10.1016/j.ebiom.2026.106168","DOIUrl":"https://doi.org/10.1016/j.ebiom.2026.106168","url":null,"abstract":"<p><strong>Background: </strong>Community health workers (CHWs) play a vital role in identifying patients within the community. To enhance their decision-making and reduce unnecessary referrals, Rwanda introduced a digital integrated disease screening tool (d-IDS), embedded within the national community Electronic Medical Records (cEMR) system. This study aimed to design, integrate, and evaluate the d-IDS to support its broader national scale-up.</p><p><strong>Methods: </strong>This study employed a pre-post effectiveness-implementation hybrid design to implement the d-IDS and evaluate its effectiveness in improving patient management at the community level in five districts during April-July 2024. The d-IDS was designed into a single decision-support workflow embedded within the cEMR platform, and deployed on CHWs' smartphones. The workflow automatically guides CHWs through case registration, symptom assessment, diagnostic testing, and treatment or referral decisions. The d-IDS tool consolidated the screening processes for tuberculosis, malaria, pneumonia, and diarrhoeal diseases. Referral data extracted from the cEMR following d-IDS implementation and retrospective data from similar period (April-July 2023) collected under the paper-based approach; Standard of Care (SOC), were analysed using Chi-square tests. Qualitative feedback from CHWs were gathered through structured interviews to assess acceptability and feasibility.</p><p><strong>Findings: </strong>The implementation of d-IDS led to a statistically significant 24.2% reduction in overall referrals to health facilities (p < 0.0001) when compared to the SOC period. Of the 3060 individuals screened using the d-IDS, 45.6% triggered further assessment, and 1687 (55.1%) were successfully managed by CHWs at the community level. Notably, in Rwamagana district, referral rates dropped from 79.8% to 32.5%, a 59.2% reduction (p < 0.0001). CHWs reported that d-IDS improved workflow efficiency, data accuracy, and decision-making compared to the paper-based approach, especially with features like offline functionality and symptom-guided screening protocols.</p><p><strong>Interpretation: </strong>The findings confirm that d-IDS is both feasible and acceptable for CHW use in community settings. It improves community-based patient management and reduces the burden on health facilities. However, close follow-up mechanisms are necessary to ensure early detection of any worsening conditions. These promising results support the future national rollout of d-IDS as a scalable solution to strengthen primary healthcare and CHW-led service delivery.</p><p><strong>Funding: </strong>The study received financial support from the United Kingdom (FCDO 40105983), Canada (DFATD 7429348) and Germany (BMZ ACT Accelerator support 25.04.2022).</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"125 ","pages":"106168"},"PeriodicalIF":10.8,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146194329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-11DOI: 10.1016/j.ebiom.2026.106155
Junhan Zhang, Celi Yang, Yuefeng Tan, Muzi Na, Evaniya Shakya, Da Zhang, Xiaojin Shi, Xiaona Na, Zhihui Li, John S Ji, Yucheng Yang, Ai Zhao
Background: The association and mechanisms between biotin and dementia remain unclear.
Methods: We investigated the association through a population and animal study. UK Biobank data were used to evaluate the association of biotin with incident dementia and brain structural alteration. To validate our findings, we established a biotin-deficient mouse model, and performed behavioural tests, immunofluorescence, RT-qPCR, Western blotting, and molecular docking.
Findings: In humans, higher biotin intake was significantly associated with reduced risks of all-cause dementia (moderate: 0.83 [0.74-0.94]; high: 0.78 [0.68-0.89]), Alzheimer's disease (AD, moderate: 0.74 [0.61-0.89]; high: 0.79 [0.64-0.98]), and delayed-onset dementia (DOD, moderate: 0.810 [0.715-0.918]; high: 0.776 [0.672-0.896]), but not vascular dementia (VD) and early-onset dementia (EOD). Neuroimaging results revealed a "pseudo-atrophy" pattern-reduced cortical volume with increased tissue intensity-resembling structural remodelling rather than neurodegeneration. In mice, biotin deficiency triggered region-specific alteration of APP, PSEN1, and APOE in the hippocampus and prefrontal cortex. It was accompanied by elevated Aβ42 levels and an increased Aβ42/40 ratio. Molecular docking suggested that biotin physically interacts with the catalytic pocket of PSEN1 and the receptor-binding domain of APOE.
Interpretation: Dietary biotin is associated with a lower risk of dementia, especially AD, potentially by inhibiting amyloidogenic processing and modulating APOE-mediated clearance. The observed neuroimaging and molecular patterns suggest that maintaining adequate biotin intake is a viable strategy for dementia prevention.
Funding: This work was supported by the National Natural Science Foundation of China (No. 82273619).
{"title":"Region-specific brain structural modulation and amyloid-β pathology associated with dietary biotin: insights into dementia neuropathology.","authors":"Junhan Zhang, Celi Yang, Yuefeng Tan, Muzi Na, Evaniya Shakya, Da Zhang, Xiaojin Shi, Xiaona Na, Zhihui Li, John S Ji, Yucheng Yang, Ai Zhao","doi":"10.1016/j.ebiom.2026.106155","DOIUrl":"https://doi.org/10.1016/j.ebiom.2026.106155","url":null,"abstract":"<p><strong>Background: </strong>The association and mechanisms between biotin and dementia remain unclear.</p><p><strong>Methods: </strong>We investigated the association through a population and animal study. UK Biobank data were used to evaluate the association of biotin with incident dementia and brain structural alteration. To validate our findings, we established a biotin-deficient mouse model, and performed behavioural tests, immunofluorescence, RT-qPCR, Western blotting, and molecular docking.</p><p><strong>Findings: </strong>In humans, higher biotin intake was significantly associated with reduced risks of all-cause dementia (moderate: 0.83 [0.74-0.94]; high: 0.78 [0.68-0.89]), Alzheimer's disease (AD, moderate: 0.74 [0.61-0.89]; high: 0.79 [0.64-0.98]), and delayed-onset dementia (DOD, moderate: 0.810 [0.715-0.918]; high: 0.776 [0.672-0.896]), but not vascular dementia (VD) and early-onset dementia (EOD). Neuroimaging results revealed a \"pseudo-atrophy\" pattern-reduced cortical volume with increased tissue intensity-resembling structural remodelling rather than neurodegeneration. In mice, biotin deficiency triggered region-specific alteration of APP, PSEN1, and APOE in the hippocampus and prefrontal cortex. It was accompanied by elevated Aβ42 levels and an increased Aβ42/40 ratio. Molecular docking suggested that biotin physically interacts with the catalytic pocket of PSEN1 and the receptor-binding domain of APOE.</p><p><strong>Interpretation: </strong>Dietary biotin is associated with a lower risk of dementia, especially AD, potentially by inhibiting amyloidogenic processing and modulating APOE-mediated clearance. The observed neuroimaging and molecular patterns suggest that maintaining adequate biotin intake is a viable strategy for dementia prevention.</p><p><strong>Funding: </strong>This work was supported by the National Natural Science Foundation of China (No. 82273619).</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"125 ","pages":"106155"},"PeriodicalIF":10.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146178488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-11DOI: 10.1016/j.ebiom.2026.106169
Hadis Ashrafizadeh, Maryam Rassouli
{"title":"Digital integrated systems in primary health care: advancing universal health coverage in low- and middle-income countries.","authors":"Hadis Ashrafizadeh, Maryam Rassouli","doi":"10.1016/j.ebiom.2026.106169","DOIUrl":"https://doi.org/10.1016/j.ebiom.2026.106169","url":null,"abstract":"","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"125 ","pages":"106169"},"PeriodicalIF":10.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146178493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-11DOI: 10.1016/j.ebiom.2026.106165
Katie Brookes, Jessica S Fear, Caitlin E M Thornton, Ling Zha, Jana Kim, Benjamin Small, Sarinya Wongsanit, Hannah R Nieto, Holly Adcock, Adam Jones, Truc T Pham, Giovanni Bottegoni, Liam R Cox, Vinodh Kannappan, Weiguang Wang, Caroline M Gorvin, Daniel G Stover, Christine Spitzweg, Sissy Jhiang, Matthew D Ringel, Moray J Campbell, Kavitha Sunassee, Philip J Blower, Kristien Boelaert, Vicki E Smith, Martin L Read, Christopher J McCabe
Background: Exploitation of the sodium iodide symporter (NIS) has potentially broad clinical application across different tumour ablative settings but often fails in aggressive cancer due to diminished transport activity. We aimed to discover whether enhancing NIS function by modulating proteostasis was targetable in vivo, as well as the clinical relevance to radioiodide (RAI) treatment of patients with cancer.
Methods: We used 3D modelling, iterative design, reformulation, RAI uptake, RNA-Seq, cell surface biotinylation assays and NanoBRET in transformed cell lines and primary thyroid cells from patients to identify new drugs targeted at enhancing NIS function and to uncover their respective mechanisms. Systemic drug responses were monitored via 99mTc pertechnetate gamma counting and SPECT/CT imaging in wild-type BALB/c and Tg-rtTA/tetO-BRAFV600E mice, as well as orthotopic NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) breast cancer.
Findings: Copper diethyldithiocarbamate (Cu(DDC)2), a metabolite of the FDA-approved drug disulfiram, modulated NIS function in thyroid and breast cancer cells (P < 0.05). Mechanistically, Cu(DDC)2 elicited a dual effect on NIS function, targeting valosin containing protein (VCP)-a key regulator of proteostasis-as well as inducing potent transcriptional responses (P < 0.05). In mice, the copper-bound metabolite stimulated NIS activity in normal thyroid tissue, thyroid tumours and in breast orthotopic tumours (P < 0.05), the latter augmented by the histone deacetylase inhibitor vorinostat (SAHA). Notably, there was clinical association of drug-perturbed genes in RAI-treated thyroid cancer, enabling construction of a robust dual risk score classifier for predicting recurrence (AUC >0.95; P < 0.001).
Interpretation: Our findings reveal a mechanistic pathway towards enhancing radionuclide uptake in vivo, with clinical relevance for RAI therapy and identifying survival indicators of recurrent disease.
Funding: This work was funded by the U.S. Department of Defense (BC201532P1), Medical Research Council (CiC/1001505 and MR/Z504828/1), British Thyroid Foundation (1002175). We further acknowledge support from the Wellcome Trust and EPSRC funded Centre for Medical Engineering at King's College London (203148/Z/16/Z), the Wellcome Multiuser Equipment Radioanalytical Facility (212885/Z/18/Z), and the EPSRC programme for Next Generation Molecular Imaging and Therapy with Radionuclides (EP/S019901/1).
背景:利用碘化钠同向转运体(NIS)在不同的肿瘤消融环境中具有潜在的广泛临床应用,但由于运输活性降低,在侵袭性癌症中往往失败。我们的目的是发现通过调节蛋白酶平衡来增强NIS功能在体内是否具有靶向性,以及与放射性碘化物(RAI)治疗癌症患者的临床相关性。方法:采用3D建模、迭代设计、重组、RAI摄取、RNA-Seq、细胞表面生物素化和NanoBRET等方法,在转化细胞系和患者原代甲状腺细胞中鉴定靶向增强NIS功能的新药,并揭示其各自的机制。通过99mTc高技术γ计数和SPECT/CT成像监测野生型BALB/c和Tg-rtTA/tetO-BRAFV600E小鼠以及原位NOD的全身药物反应。Cg-Prkdcscid il2rgtm1wj1 /SzJ (NSG)乳腺癌。发现:fda批准的药物双硫仑的代谢物二乙基二硫代氨基甲酸铜(Cu(DDC)2)可调节甲状腺和乳腺癌细胞中的NIS功能(P < 0.05)。从机制上讲,Cu(DDC)2对NIS的功能有双重影响,既针对valosin containing protein (VCP)——蛋白质稳态的关键调节因子,又诱导了有效的转录反应(P < 0.05)。在小鼠中,铜结合代谢物刺激正常甲状腺组织、甲状腺肿瘤和乳腺原位肿瘤中的NIS活性(P < 0.05),组蛋白去乙酰化酶抑制剂伏立诺他(SAHA)增强了后者的活性。值得注意的是,经放射治疗的甲状腺癌中存在药物干扰基因的临床关联,这使得构建了一个强大的双重风险评分分类器来预测复发(AUC >0.95; P < 0.001)。解释:我们的研究结果揭示了增强体内放射性核素摄取的机制途径,与RAI治疗和确定复发性疾病的生存指标具有临床相关性。本工作由美国国防部(BC201532P1)、医学研究委员会(CiC/1001505和MR/Z504828/1)、英国甲状腺基金会(1002175)资助。我们进一步感谢惠康基金会和EPSRC资助的伦敦国王学院医学工程中心(203148/Z/16/Z)、惠康多用户设备放射分析设施(212885/Z/18/Z)以及EPSRC下一代放射性核素分子成像和治疗项目(EP/S019901/1)的支持。
{"title":"Disulfiram metabolite Cu(DDC)<sub>2</sub> enhances radionuclide uptake in vivo revealing insights into tumoural ablation resistance.","authors":"Katie Brookes, Jessica S Fear, Caitlin E M Thornton, Ling Zha, Jana Kim, Benjamin Small, Sarinya Wongsanit, Hannah R Nieto, Holly Adcock, Adam Jones, Truc T Pham, Giovanni Bottegoni, Liam R Cox, Vinodh Kannappan, Weiguang Wang, Caroline M Gorvin, Daniel G Stover, Christine Spitzweg, Sissy Jhiang, Matthew D Ringel, Moray J Campbell, Kavitha Sunassee, Philip J Blower, Kristien Boelaert, Vicki E Smith, Martin L Read, Christopher J McCabe","doi":"10.1016/j.ebiom.2026.106165","DOIUrl":"https://doi.org/10.1016/j.ebiom.2026.106165","url":null,"abstract":"<p><strong>Background: </strong>Exploitation of the sodium iodide symporter (NIS) has potentially broad clinical application across different tumour ablative settings but often fails in aggressive cancer due to diminished transport activity. We aimed to discover whether enhancing NIS function by modulating proteostasis was targetable in vivo, as well as the clinical relevance to radioiodide (RAI) treatment of patients with cancer.</p><p><strong>Methods: </strong>We used 3D modelling, iterative design, reformulation, RAI uptake, RNA-Seq, cell surface biotinylation assays and NanoBRET in transformed cell lines and primary thyroid cells from patients to identify new drugs targeted at enhancing NIS function and to uncover their respective mechanisms. Systemic drug responses were monitored via <sup>99m</sup>Tc pertechnetate gamma counting and SPECT/CT imaging in wild-type BALB/c and Tg-rtTA/tetO-BRAF<sup>V600E</sup> mice, as well as orthotopic NOD.Cg-Prkdc<sup>scid</sup> Il2rg<sup>tm1Wjl</sup>/SzJ (NSG) breast cancer.</p><p><strong>Findings: </strong>Copper diethyldithiocarbamate (Cu(DDC)<sub>2</sub>), a metabolite of the FDA-approved drug disulfiram, modulated NIS function in thyroid and breast cancer cells (P < 0.05). Mechanistically, Cu(DDC)<sub>2</sub> elicited a dual effect on NIS function, targeting valosin containing protein (VCP)-a key regulator of proteostasis-as well as inducing potent transcriptional responses (P < 0.05). In mice, the copper-bound metabolite stimulated NIS activity in normal thyroid tissue, thyroid tumours and in breast orthotopic tumours (P < 0.05), the latter augmented by the histone deacetylase inhibitor vorinostat (SAHA). Notably, there was clinical association of drug-perturbed genes in RAI-treated thyroid cancer, enabling construction of a robust dual risk score classifier for predicting recurrence (AUC >0.95; P < 0.001).</p><p><strong>Interpretation: </strong>Our findings reveal a mechanistic pathway towards enhancing radionuclide uptake in vivo, with clinical relevance for RAI therapy and identifying survival indicators of recurrent disease.</p><p><strong>Funding: </strong>This work was funded by the U.S. Department of Defense (BC201532P1), Medical Research Council (CiC/1001505 and MR/Z504828/1), British Thyroid Foundation (1002175). We further acknowledge support from the Wellcome Trust and EPSRC funded Centre for Medical Engineering at King's College London (203148/Z/16/Z), the Wellcome Multiuser Equipment Radioanalytical Facility (212885/Z/18/Z), and the EPSRC programme for Next Generation Molecular Imaging and Therapy with Radionuclides (EP/S019901/1).</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"125 ","pages":"106165"},"PeriodicalIF":10.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146178451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Lung cancer is mainly diagnosed in elderly adults, yet the incidence of early-onset disease in people aged ≤45 years is increasing. Current screening strategies largely target elder populations, leaving younger individuals at risk of delayed diagnosis and adverse outcomes. Phenotypic Age Acceleration (PhenoAgeAccel), which indicates the difference between biological age and chronological age, has been associated with cancer susceptibility, but its role in early-onset lung cancer is unclear.
Methods: We performed a case-control and prognostic cohort study in China, including 222 early-onset lung cancer patients and 222 age- and sex-matched healthy volunteers, and externally validated findings in the UK Biobank. PhenoAgeAccel was calculated from routinely available haematological and biochemical markers. Logistic regression models estimated associations between PhenoAgeAccel and lung cancer risk. Survival analyses assessed the relationship between PhenoAgeAccel and overall survival among early-onset patients.
Findings: Early-onset lung cancer patients had substantially higher PhenoAgeAccel than matched controls (P < 0.001). PhenoAgeAccel was associated with a dose-dependent increase in early-onset lung cancer risk (odds ratio [OR] = 1.18; 95% CI: 1.14-1.23). Subgroup analyses by chronological age demonstrated a stronger association in earlier adulthood, whereas associations among elder adults (≥65 years) were not significant. In early-onset patients, higher PhenoAgeAccel predicted worse overall survival (hazard ratio [HR] = 2.17; 95% CI: 1.20-3.93). Results were corroborated in the UK Biobank cohort.
Interpretation: PhenoAgeAccel is positively associated with both a greater risk of early-onset lung cancer and poorer prognosis, supporting its potential utility for early detection and risk stratification in younger populations.
Funding: National Natural Science Foundation of China (no. 82303969); Beijing Xisike Clinical Oncology Research Foundation (no. Y-2024AZ [EGFR]MS-0079); Beijing Natural Science Foundation (no. 7222144).
{"title":"Phenotypic age acceleration and early-onset lung cancer: a case-control and prognostic cohort study involving multiple clinical centres with validation in the UK Biobank.","authors":"Ruolin Gao, Yuxuan Liao, Qiwen Zheng, Zhijian Xu, Xiaowei Zhao, Qinxiang Guo, Zhijie Wang, Jianchun Duan, Rui Wan, Jiachen Xu, Kailun Fei, Boyang Sun, Wei Zhuang, Hua Bai, Yanhui Cheng, Jia Zhong, Jie Wang","doi":"10.1016/j.ebiom.2026.106162","DOIUrl":"https://doi.org/10.1016/j.ebiom.2026.106162","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer is mainly diagnosed in elderly adults, yet the incidence of early-onset disease in people aged ≤45 years is increasing. Current screening strategies largely target elder populations, leaving younger individuals at risk of delayed diagnosis and adverse outcomes. Phenotypic Age Acceleration (PhenoAgeAccel), which indicates the difference between biological age and chronological age, has been associated with cancer susceptibility, but its role in early-onset lung cancer is unclear.</p><p><strong>Methods: </strong>We performed a case-control and prognostic cohort study in China, including 222 early-onset lung cancer patients and 222 age- and sex-matched healthy volunteers, and externally validated findings in the UK Biobank. PhenoAgeAccel was calculated from routinely available haematological and biochemical markers. Logistic regression models estimated associations between PhenoAgeAccel and lung cancer risk. Survival analyses assessed the relationship between PhenoAgeAccel and overall survival among early-onset patients.</p><p><strong>Findings: </strong>Early-onset lung cancer patients had substantially higher PhenoAgeAccel than matched controls (P < 0.001). PhenoAgeAccel was associated with a dose-dependent increase in early-onset lung cancer risk (odds ratio [OR] = 1.18; 95% CI: 1.14-1.23). Subgroup analyses by chronological age demonstrated a stronger association in earlier adulthood, whereas associations among elder adults (≥65 years) were not significant. In early-onset patients, higher PhenoAgeAccel predicted worse overall survival (hazard ratio [HR] = 2.17; 95% CI: 1.20-3.93). Results were corroborated in the UK Biobank cohort.</p><p><strong>Interpretation: </strong>PhenoAgeAccel is positively associated with both a greater risk of early-onset lung cancer and poorer prognosis, supporting its potential utility for early detection and risk stratification in younger populations.</p><p><strong>Funding: </strong>National Natural Science Foundation of China (no. 82303969); Beijing Xisike Clinical Oncology Research Foundation (no. Y-2024AZ [EGFR]MS-0079); Beijing Natural Science Foundation (no. 7222144).</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"125 ","pages":"106162"},"PeriodicalIF":10.8,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146164601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-10DOI: 10.1016/j.ebiom.2026.106154
Changyuan Hu, Sung-Young Shin, Yanan Wang, Chenbin Chen, Pei Liu, Rita A Busuttil, Yunjian Wu, Catriona A McLean, Hongying Shi, Terry Kwok, Lan K Nguyen, Jiangning Song, Alex Boussioutas, Xian Shen, Roger J Daly
Background: Most gastric cancer (GC) patients receive uniform treatment due to the lack of predictive biomarkers for chemotherapy or radiotherapy. We previously identified epithelial-mesenchymal transition (EMT) and metabolism subgroups in GC cell lines based on kinomic profiles, but their clinical relevance was unknown.
Methods: We developed an ensemble model using 37 kinases that differed between cell line subgroups to classify stage II-IV GC into EMT and metabolism subgroups. Survival differences between those who received chemotherapy or radiotherapy and those who did not were compared within each subgroup to validate the model effectiveness in predicting therapeutic response. An iteration approach was further applied to optimise and validate the feature set via multiple publicly-available datasets.
Findings: An 11-kinase signature stratified 893 patients into two subgroups. The metabolism subgroup showed significantly better survival with chemotherapy (HRmultivariable = 0.56) and radiotherapy (HRmultivariable = 0.55), whereas no such improvement was observed in the EMT subgroup. Significant interaction between kinomic subgroups and treatments were noted. The chemotherapy benefits between subgroups were greater with 5-fluorouracil-based regimens than cisplatin-based ones. This kinomic taxonomy was distinct from Lauren classification and previous transcriptomic subtypes and also suggested differential therapeutic vulnerabilities between subgroups.
Interpretation: This model holds promise for optimising chemotherapy and radiotherapy decisions for GC.
Funding: Biomedicine Discovery Scholarship and Graduate Research Completion Award, Monash University; National Natural Science Foundation of China (81602165) (C.H.). Australian Research Council Centre of Excellence for the Mathematical Analysis of Cellular Systems (CE230100001) (L.K.N.).
{"title":"Identification and validation of an 11-kinase signature that predicts chemo- and radiosensitivity in gastric cancer.","authors":"Changyuan Hu, Sung-Young Shin, Yanan Wang, Chenbin Chen, Pei Liu, Rita A Busuttil, Yunjian Wu, Catriona A McLean, Hongying Shi, Terry Kwok, Lan K Nguyen, Jiangning Song, Alex Boussioutas, Xian Shen, Roger J Daly","doi":"10.1016/j.ebiom.2026.106154","DOIUrl":"https://doi.org/10.1016/j.ebiom.2026.106154","url":null,"abstract":"<p><strong>Background: </strong>Most gastric cancer (GC) patients receive uniform treatment due to the lack of predictive biomarkers for chemotherapy or radiotherapy. We previously identified epithelial-mesenchymal transition (EMT) and metabolism subgroups in GC cell lines based on kinomic profiles, but their clinical relevance was unknown.</p><p><strong>Methods: </strong>We developed an ensemble model using 37 kinases that differed between cell line subgroups to classify stage II-IV GC into EMT and metabolism subgroups. Survival differences between those who received chemotherapy or radiotherapy and those who did not were compared within each subgroup to validate the model effectiveness in predicting therapeutic response. An iteration approach was further applied to optimise and validate the feature set via multiple publicly-available datasets.</p><p><strong>Findings: </strong>An 11-kinase signature stratified 893 patients into two subgroups. The metabolism subgroup showed significantly better survival with chemotherapy (HR<sub>multivariable</sub> = 0.56) and radiotherapy (HR<sub>multivariable</sub> = 0.55), whereas no such improvement was observed in the EMT subgroup. Significant interaction between kinomic subgroups and treatments were noted. The chemotherapy benefits between subgroups were greater with 5-fluorouracil-based regimens than cisplatin-based ones. This kinomic taxonomy was distinct from Lauren classification and previous transcriptomic subtypes and also suggested differential therapeutic vulnerabilities between subgroups.</p><p><strong>Interpretation: </strong>This model holds promise for optimising chemotherapy and radiotherapy decisions for GC.</p><p><strong>Funding: </strong>Biomedicine Discovery Scholarship and Graduate Research Completion Award, Monash University; National Natural Science Foundation of China (81602165) (C.H.). Australian Research Council Centre of Excellence for the Mathematical Analysis of Cellular Systems (CE230100001) (L.K.N.).</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"125 ","pages":"106154"},"PeriodicalIF":10.8,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146178500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-10DOI: 10.1016/j.ebiom.2026.106160
Shengmei Zhang, Chang Gao, Ruonan Li, Jia Lv, Jingjing Xu, Maohua Miao, Hong Liang, De-Xiang Xu, Bo Wang, Yichao Huang
Background: Early-life exposure to exogenous chemicals can disrupt neurodevelopment. Perfluorohexanesulfonic acid (PFHxS), a legacy PFAS widely used and detected globally, remains poorly studied for its neurotoxicity.
Methods: CD-1 mice (n = 90 dams) were exposed to human-relevant dose of PFHxS from gestational day (GD) 0-17. PFHxS levels were measured in maternal plasma and foetal/offspring medial prefrontal cortex (mPFC) (GD 18, postnatal weeks [PNW] 4 and 10) using liquid chromatography tandem mass-spectrometry (LC-MS/MS). Offspring social behaviour was assessed with the Three-Chamber social test. Neurotransmitters in mPFC of PNW 10 offspring were profiled by LC-MS/MS, transcriptomics was performed on GD 18 and PNW 4 mPFC, GABAergic neurons were quantified by immunofluorescence, and glutamate decarboxylase (GAD) expression by western blotting. PFHxS-GAD interactions were examined via molecular docking and microscale thermophoresis (MST).
Findings: Maternal plasma reached 5.1 ± 0.1 ng/mL, equivalent to human biomonitoring data, and PFHxS accumulated in foetal mPFC (68.1 ± 4.1 pg/g). PFHxS exposure induced social deficits at PNW 4 and 10, which were more pronounced in males. The mPFC of PFHxS exposed offspring exhibited an excitatory-tilted neurotransmitter profile, feature with reduced γ-aminobutyric acid (GABA, 90.6 ± 12.2 vs. 70.2 ± 4.3 μg/g, p = 0.008). The differentially expressed genes were enriched in GABAergic and synaptic signalling pathways. Despite unchanged percentage of GABAergic neuron and GAD expression, metabolite GABA/glutamate ratio was attenuated, suggesting impaired GAD function. Both molecular docking and MST suggested moderate-to-strong binding affinity between PFHxS and GAD, affecting GABA synthesis.
Interpretation: Gestational PFHxS exposure at human-relevant levels impairs offspring social behaviour, likely via disruption of GAD-mediated imbalance in excitation/inhibition.
Funding: This work was provided by grants from the National Natural Science Foundation of China (82404221 and 82373586), Anhui Provincial Natural Science Foundation (2308085Y50 and 2408085QH275), Education Department of Anhui Province for Excellent Young Scientist (2022AH030076), and funding from Center for Big Data and Population Health of IHM (JKS2022020).
{"title":"Effects of gestational perfluorohexanesulfonic acid exposure at human realistic dose on social communication deficit in mouse offspring.","authors":"Shengmei Zhang, Chang Gao, Ruonan Li, Jia Lv, Jingjing Xu, Maohua Miao, Hong Liang, De-Xiang Xu, Bo Wang, Yichao Huang","doi":"10.1016/j.ebiom.2026.106160","DOIUrl":"https://doi.org/10.1016/j.ebiom.2026.106160","url":null,"abstract":"<p><strong>Background: </strong>Early-life exposure to exogenous chemicals can disrupt neurodevelopment. Perfluorohexanesulfonic acid (PFHxS), a legacy PFAS widely used and detected globally, remains poorly studied for its neurotoxicity.</p><p><strong>Methods: </strong>CD-1 mice (n = 90 dams) were exposed to human-relevant dose of PFHxS from gestational day (GD) 0-17. PFHxS levels were measured in maternal plasma and foetal/offspring medial prefrontal cortex (mPFC) (GD 18, postnatal weeks [PNW] 4 and 10) using liquid chromatography tandem mass-spectrometry (LC-MS/MS). Offspring social behaviour was assessed with the Three-Chamber social test. Neurotransmitters in mPFC of PNW 10 offspring were profiled by LC-MS/MS, transcriptomics was performed on GD 18 and PNW 4 mPFC, GABAergic neurons were quantified by immunofluorescence, and glutamate decarboxylase (GAD) expression by western blotting. PFHxS-GAD interactions were examined via molecular docking and microscale thermophoresis (MST).</p><p><strong>Findings: </strong>Maternal plasma reached 5.1 ± 0.1 ng/mL, equivalent to human biomonitoring data, and PFHxS accumulated in foetal mPFC (68.1 ± 4.1 pg/g). PFHxS exposure induced social deficits at PNW 4 and 10, which were more pronounced in males. The mPFC of PFHxS exposed offspring exhibited an excitatory-tilted neurotransmitter profile, feature with reduced γ-aminobutyric acid (GABA, 90.6 ± 12.2 vs. 70.2 ± 4.3 μg/g, p = 0.008). The differentially expressed genes were enriched in GABAergic and synaptic signalling pathways. Despite unchanged percentage of GABAergic neuron and GAD expression, metabolite GABA/glutamate ratio was attenuated, suggesting impaired GAD function. Both molecular docking and MST suggested moderate-to-strong binding affinity between PFHxS and GAD, affecting GABA synthesis.</p><p><strong>Interpretation: </strong>Gestational PFHxS exposure at human-relevant levels impairs offspring social behaviour, likely via disruption of GAD-mediated imbalance in excitation/inhibition.</p><p><strong>Funding: </strong>This work was provided by grants from the National Natural Science Foundation of China (82404221 and 82373586), Anhui Provincial Natural Science Foundation (2308085Y50 and 2408085QH275), Education Department of Anhui Province for Excellent Young Scientist (2022AH030076), and funding from Center for Big Data and Population Health of IHM (JKS2022020).</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"125 ","pages":"106160"},"PeriodicalIF":10.8,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146164662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-10DOI: 10.1016/j.ebiom.2026.106152
Cecilie Bæch-Laursen, Jon Vergara Ucin, Katrine Douglas Galsgaard, Jesus Llana, Hannelouise Kissow, Jens Frederik Rehfeld, Jens Juul Holst, Bente Klarlund Pedersen, Paula Sanchis
Background: Physical activity helps maintain a healthy stable body weight. One mechanism underlying this beneficial effect could be the improved coupling between energy intake and expenditure, since hunger and satiety are better regulated in active individuals. Whether this enhancement of appetite control by exercise is reflected in overall adaptations in the gut and gut-brain communication remains poorly defined.
Methods: We investigated how increased physical activity alters gut morphology, intestinal endocrine function, and central appetite signalling in C57BL/6NRJ male mice fed ad-libitum chow diet. We assessed intestinal growth, L-cell density, and glucose-stimulated endocrine secretion, as well as circulating levels and gene expression of gut derived peptide hormones. Additionally, we quantified neuronal activity in the brainstem dorsal vagal complex following a fasting-refeeding intervention and examined the effects of PYY, CCK, ghrelin, and GLP-1 administration on food intake in sedentary and physically active mice. Depending on the dataset, unpaired or paired Student's t-tests, two-way ANOVA followed by Bonferroni's post hoc test, simple linear regression or a linear mixed-effects model were applied. Statistical significance was set at P < 0.05.
Findings: Physical activity induced a slight growth of the small intestine, increased L-cell density, and enhanced glucose-stimulated GLP-1 secretion. It altered the circulating levels of PYY and ghrelin and increased the dynamic regulation of neuronal activity in the area postrema and nucleus tractus solitarius. Active mice displayed greater sensitivity to gut-derived hormones PYY, CCK, and ghrelin exerting amplified and prolonged effects on food intake, whereas native GLP-1 showed no effect, likely due to its short half-life. Physical activity prevented post-fasting hyperphagia, thereby promoting sustained maintenance of fasting-induced weight loss.
Interpretation: The findings demonstrate that physical activity promotes adaptations in the gut and gut-to-brain communication possibly enhancing the responsiveness to appetite-regulating signals. Such adaptations may strengthen the alignment between energy intake and expenditure to support body weight maintenance.
Funding: This study was supported by Novo Nordisk Foundation (0059436) and Trygfonden Centre for Physical Activity Research (101390, 20045, 125132, and 177225). P.S. is supported by Lundbeck Foundation (R380-2021-1300).
{"title":"Physical activity promotes gut adaptation, nutrient responsiveness, and sensitivity to gut peptides in male mice.","authors":"Cecilie Bæch-Laursen, Jon Vergara Ucin, Katrine Douglas Galsgaard, Jesus Llana, Hannelouise Kissow, Jens Frederik Rehfeld, Jens Juul Holst, Bente Klarlund Pedersen, Paula Sanchis","doi":"10.1016/j.ebiom.2026.106152","DOIUrl":"https://doi.org/10.1016/j.ebiom.2026.106152","url":null,"abstract":"<p><strong>Background: </strong>Physical activity helps maintain a healthy stable body weight. One mechanism underlying this beneficial effect could be the improved coupling between energy intake and expenditure, since hunger and satiety are better regulated in active individuals. Whether this enhancement of appetite control by exercise is reflected in overall adaptations in the gut and gut-brain communication remains poorly defined.</p><p><strong>Methods: </strong>We investigated how increased physical activity alters gut morphology, intestinal endocrine function, and central appetite signalling in C57BL/6NRJ male mice fed ad-libitum chow diet. We assessed intestinal growth, L-cell density, and glucose-stimulated endocrine secretion, as well as circulating levels and gene expression of gut derived peptide hormones. Additionally, we quantified neuronal activity in the brainstem dorsal vagal complex following a fasting-refeeding intervention and examined the effects of PYY, CCK, ghrelin, and GLP-1 administration on food intake in sedentary and physically active mice. Depending on the dataset, unpaired or paired Student's t-tests, two-way ANOVA followed by Bonferroni's post hoc test, simple linear regression or a linear mixed-effects model were applied. Statistical significance was set at P < 0.05.</p><p><strong>Findings: </strong>Physical activity induced a slight growth of the small intestine, increased L-cell density, and enhanced glucose-stimulated GLP-1 secretion. It altered the circulating levels of PYY and ghrelin and increased the dynamic regulation of neuronal activity in the area postrema and nucleus tractus solitarius. Active mice displayed greater sensitivity to gut-derived hormones PYY, CCK, and ghrelin exerting amplified and prolonged effects on food intake, whereas native GLP-1 showed no effect, likely due to its short half-life. Physical activity prevented post-fasting hyperphagia, thereby promoting sustained maintenance of fasting-induced weight loss.</p><p><strong>Interpretation: </strong>The findings demonstrate that physical activity promotes adaptations in the gut and gut-to-brain communication possibly enhancing the responsiveness to appetite-regulating signals. Such adaptations may strengthen the alignment between energy intake and expenditure to support body weight maintenance.</p><p><strong>Funding: </strong>This study was supported by Novo Nordisk Foundation (0059436) and Trygfonden Centre for Physical Activity Research (101390, 20045, 125132, and 177225). P.S. is supported by Lundbeck Foundation (R380-2021-1300).</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"125 ","pages":"106152"},"PeriodicalIF":10.8,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146164612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Antibiotic abuse has become a top public health problem worldwide. Ciprofloxacin (CIP) has the highest detection rate in human but its association with unexplained miscarriage (UM) is completely unknown. Senescence is a ubiquitous cellular process but its association with UM is still unclear.
Methods: We combined case-control study using a UM case-control group and in vitro functional assays using mouse model and human trophoblast HTR-8/SVneo cells. The associations between environmental exposure to CIP and cell senescence were explored. Trophoblast cell senescence, the mitochondrial dysfunctions, and the TRIM21-mediated ubiquitination degradation of MFF were investigated.
Findings: Higher urinary CIP levels are associated with villous tissue senescence and woman miscarriage. CIP-exposed mouse model further confirms that CIP exposure causes placental senescence to induce mouse miscarriage. Mechanistically, CIP up-regulates tripartite motif containing 21 (TRIM21) levels, promotes TRIM21-mediated ubiquitination degradation of mitochondrial fission factor (MFF), and thus reduces MFF levels. Subsequently, the reduced MFF causes mitochondrial dysfunctions and cell senescence, further inducing miscarriage.
Interpretation: Collectively, this study discovers new risk of CIP exposure on miscarriage, explores pathogenesis and biological mechanisms of CIP-induced miscarriage, provides targets for treatment against miscarriage, and describes the crosstalk among environmental antibiotics, biological mechanisms, and reproductive health.
Funding: This work was supported by the NSFC (NSFC No. 82373602 and No. 82571347), SMRF (No. B2303002), GBABRF (2023B1515120054 and 2023A1515110497), NSFC Joint Fund Key Support Project (grant no. U24A20748), the JITCBR (202407), HCGP (A2024281), SSTP (No. JCYJ20220530144403008, JCYJ20220818103607015, JCYJ20230807111401002, JCYJ20240813180400002, and JCYJ20241202152800001), CRSFFWJMF 320.6750.2022-06-47, FHRP (No. FTWS011 and FTWS2022002).
{"title":"Environmental ciprofloxacin triggers pregnancy loss: senescence-driven miscarriage via TRIM21-mediated MFF degradation.","authors":"Yi Sun 孙义, Yanbing Lin 林晏冰, Shuaishuai Xing 幸帅帅, Wenxin Huang 黄文欣, Yanxin Wang, Geng Guo, Haijun Yan, Depeng Zhao, Wenli Cheng, Zhengzhong Wu, Chenghui Huang, Zhihong Zhang, Linlin Wu 吴琳琳, Qingzhi Hou 侯青芝, Huidong Zhang 张慧东","doi":"10.1016/j.ebiom.2026.106146","DOIUrl":"10.1016/j.ebiom.2026.106146","url":null,"abstract":"<p><strong>Background: </strong>Antibiotic abuse has become a top public health problem worldwide. Ciprofloxacin (CIP) has the highest detection rate in human but its association with unexplained miscarriage (UM) is completely unknown. Senescence is a ubiquitous cellular process but its association with UM is still unclear.</p><p><strong>Methods: </strong>We combined case-control study using a UM case-control group and in vitro functional assays using mouse model and human trophoblast HTR-8/SVneo cells. The associations between environmental exposure to CIP and cell senescence were explored. Trophoblast cell senescence, the mitochondrial dysfunctions, and the TRIM21-mediated ubiquitination degradation of MFF were investigated.</p><p><strong>Findings: </strong>Higher urinary CIP levels are associated with villous tissue senescence and woman miscarriage. CIP-exposed mouse model further confirms that CIP exposure causes placental senescence to induce mouse miscarriage. Mechanistically, CIP up-regulates tripartite motif containing 21 (TRIM21) levels, promotes TRIM21-mediated ubiquitination degradation of mitochondrial fission factor (MFF), and thus reduces MFF levels. Subsequently, the reduced MFF causes mitochondrial dysfunctions and cell senescence, further inducing miscarriage.</p><p><strong>Interpretation: </strong>Collectively, this study discovers new risk of CIP exposure on miscarriage, explores pathogenesis and biological mechanisms of CIP-induced miscarriage, provides targets for treatment against miscarriage, and describes the crosstalk among environmental antibiotics, biological mechanisms, and reproductive health.</p><p><strong>Funding: </strong>This work was supported by the NSFC (NSFC No. 82373602 and No. 82571347), SMRF (No. B2303002), GBABRF (2023B1515120054 and 2023A1515110497), NSFC Joint Fund Key Support Project (grant no. U24A20748), the JITCBR (202407), HCGP (A2024281), SSTP (No. JCYJ20220530144403008, JCYJ20220818103607015, JCYJ20230807111401002, JCYJ20240813180400002, and JCYJ20241202152800001), CRSFFWJMF 320.6750.2022-06-47, FHRP (No. FTWS011 and FTWS2022002).</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"125 ","pages":"106146"},"PeriodicalIF":10.8,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12906125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}